Patent classifications
A61K31/10
Composition and method for orally administering one or more active agents to a pet
A composition and method for administering an active agent to a pet, such as a dog, a cat or a horse. The composition may comprise a yogurt-based chewable delivery matrix and a plurality of water-soluble film pieces dispersed throughout the chewable delivery matrix. The composition may also comprise a delivery matrix having at least 15% by weight of crude protein and a plurality of water-soluble film pieces dispersed throughout the delivery matrix. The plurality of water-soluble film pieces encompass an active agent therein, wherein the active agent is rapidly released from the composition upon contact with saliva from the pet. At least a portion of the released active agents may be oromucosally absorbed by the pet.
Composition and method for orally administering one or more active agents to a pet
A composition and method for administering an active agent to a pet, such as a dog, a cat or a horse. The composition may comprise a yogurt-based chewable delivery matrix and a plurality of water-soluble film pieces dispersed throughout the chewable delivery matrix. The composition may also comprise a delivery matrix having at least 15% by weight of crude protein and a plurality of water-soluble film pieces dispersed throughout the delivery matrix. The plurality of water-soluble film pieces encompass an active agent therein, wherein the active agent is rapidly released from the composition upon contact with saliva from the pet. At least a portion of the released active agents may be oromucosally absorbed by the pet.
LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Disclosed in the present invention is a lysosome-targeting antibody-drug conjugate and use thereof. The structure of the antibody-drug conjugate is Dr.sub.n1AbO.sub.n2; wherein, Dr is a drug, Ab is an antibody, and O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosomal targeting ability of the antibody-drug conjugate; n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.
LYSOSOME-TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF
Disclosed in the present invention is a lysosome-targeting antibody-drug conjugate and use thereof. The structure of the antibody-drug conjugate is Dr.sub.n1AbO.sub.n2; wherein, Dr is a drug, Ab is an antibody, and O is a lysosome-targeting small molecule or a functional peptide for increasing the lysosomal targeting ability of the antibody-drug conjugate; n1 and n2 are integers greater than or equal to 1, and n1 and n2 are identical or different.
COMPOSITION WITH DRUG MICRO-NANO PARTICLES OF AN ANTI-CANCER AGENT
The present invention relates to a composition comprising a water-insoluble anti-cancer agent present as surface modified and unmodified drop particles in water, a method for producing such a composition, a lyophilizate of such a composition and such a composition for use in the treatment of cancer.
COMPOSITION WITH DRUG MICRO-NANO PARTICLES OF AN ANTI-CANCER AGENT
The present invention relates to a composition comprising a water-insoluble anti-cancer agent present as surface modified and unmodified drop particles in water, a method for producing such a composition, a lyophilizate of such a composition and such a composition for use in the treatment of cancer.
MECHANOCHEMICAL DYNAMIC FOR FOCAL CANCER TREATMENT
Provided herein are compositions and methods for mechanochemical dynamic therapy.
MECHANOCHEMICAL DYNAMIC FOR FOCAL CANCER TREATMENT
Provided herein are compositions and methods for mechanochemical dynamic therapy.
Compounds, compositions, and methods for the treatment and prevention of avian pathogenic <i>E. coli </i>(APEC)
Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.
Compounds, compositions, and methods for the treatment and prevention of avian pathogenic <i>E. coli </i>(APEC)
Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.